Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
peanut allergy treatment |
| gptkbp:activeIngredient |
peanut protein
|
| gptkbp:approvedBy |
children aged 4 to 11 years
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:developedBy |
gptkb:DBV_Technologies
|
| gptkbp:form |
musical composition
|
| https://www.w3.org/2000/01/rdf-schema#label |
Viaskin Peanut
|
| gptkbp:indication |
peanut allergy
|
| gptkbp:marketedAs |
gptkb:DBV_Technologies
|
| gptkbp:mechanismOfAction |
epicutaneous immunotherapy
|
| gptkbp:regulates |
gptkb:FDA
gptkb:EMA approved |
| gptkbp:routeOfAdministration |
transdermal
|
| gptkbp:sideEffect |
pruritus
skin irritation erythema anaphylaxis (rare) |
| gptkbp:therapeuticArea |
gptkb:allergy
|
| gptkbp:bfsParent |
gptkb:DBV
|
| gptkbp:bfsLayer |
6
|